These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36395587)

  • 1. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Ezzati A; Buse DC; Fanning KM; Reed ML; Martin VT; Lipton RB
    Clin Neurol Neurosurg; 2022 Dec; 223():107511. PubMed ID: 36395587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine.
    Ezzati A; Fanning KM; Reed ML; Lipton RB
    Headache; 2023 Mar; 63(3):342-352. PubMed ID: 36748728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
    Ezzati A; Fanning KM; Buse DC; Pavlovic JM; Armand CE; Reed ML; Martin VT; Lipton RB
    Headache; 2022 Jun; 62(6):755-765. PubMed ID: 35546653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
    Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
    Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
    J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Lipton RB; Buse DC; Dodick DW; Schwedt TJ; Singh P; Munjal S; Fanning K; Bostic Bs R; Reed ML
    Headache; 2021 Jan; 61(1):103-116. PubMed ID: 33326608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study.
    Hutchinson S; Lipton RB; Ailani J; Reed ML; Fanning KM; Adams AM; Buse DC
    Mayo Clin Proc; 2020 Apr; 95(4):709-718. PubMed ID: 32247344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
    Lipton RB; Manack Adams A; Buse DC; Fanning KM; Reed ML
    Headache; 2016 Sep; 56(8):1280-9. PubMed ID: 27349336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of switching acute treatment on disability in migraine patients using triptans.
    Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
    Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Lipton RB; Hutchinson S; Ailani J; Reed ML; Fanning KM; Manack Adams A; Buse DC
    Headache; 2019 Nov; 59(10):1762-1772. PubMed ID: 31544244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of medication overuse headache across classes of treatments for acute migraine.
    Thorlund K; Sun-Edelstein C; Druyts E; Kanters S; Ebrahim S; Bhambri R; Ramos E; Mills EJ; Lanteri-Minet M; Tepper S
    J Headache Pain; 2016 Dec; 17(1):107. PubMed ID: 27882516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
    Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
    Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.